Back

Comprehensive characterization of early-stage Non-Small Cell Lung cancers with multi-modal data integration

Schulz, D.; Morfouace, M.; Fernandez, B. P.; Mozejko, M.; Deglise, S.; Daniel, M.; Eling, N.; Hong, H. S.; Tissot, S.; Rusakiewicz, S.; Trefzer, T.; Merlevede, J.; Marzetta, F.; de Souza, N.; Wojtowicz, D.; Szczurek, E.; Besse, B.; Bodenmiller, B.

2025-11-13 oncology
10.1101/2025.11.10.25339890 medRxiv
Show abstract

Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related death despite the availability of therapies targeting the tumor microenvironment (TME) and/or the tumor. Immunotherapy and novel targeted therapy have improved the management of NSCLC, but the heterogeneity of the disease still hampers treatment efficacy as well as further therapeutic advances. Here, we used spatial single-cell data complemented with bulk RNAseq and whole exome sequencing to investigate the TME of 192 resected, mostly early-stage NSCLC tumors and to characterize associations of genetic, clinical and lifestyle factors with cellular and histological properties of the TME. We found, that the TME of squamous cell carcinoma (LUSC) harbored stronger signs of inflammation and immune exhaustion than adenocarcinoma (LUAD), but interestingly that elevated PD-L1 expression was associated with inflammation and markers of lymphocyte activation/exhaustion only in LUAD. Smoking correlated with T cell infiltration and TP53 mutation in LUAD, and TP53 mutation was associated with proliferation of tumor cells. In both histologies, naive and BCL2+ T cells decreased with higher clinical stages. EGFR-driven tumors showed fewer proliferating, activated and exhausted T cells, but more CD4 T cells and HLA-DR+ tumor cells, than tumors with wild type EGFR. Multi-modal integration of our four data types showed that most variation in our cohort was along the axes of histology, smoking, TP53 mutation, and inflammation. Our integration identified histology-specific prognostic signatures, with a LUSC-enriched profile of proliferation, inflammation, and smoking associated with poor prognosis in LUAD. In summary, we provide a rich, multimodal, single-cell characterization of a large NSCLC cohort as a resource and suggest that future investigations of biomarkers for ICI in NSCLC will benefit from stratification by histology.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Cancer Cell
38 papers in training set
Top 0.1%
32.2%
2
iScience
1063 papers in training set
Top 2%
6.2%
3
Nature Communications
4913 papers in training set
Top 34%
4.7%
4
Molecular Cancer
14 papers in training set
Top 0.1%
3.9%
5
Journal of Translational Medicine
46 papers in training set
Top 0.2%
3.5%
50% of probability mass above
6
Cell Reports
1338 papers in training set
Top 16%
3.5%
7
Scientific Reports
3102 papers in training set
Top 46%
2.5%
8
Molecular Oncology
50 papers in training set
Top 0.2%
2.3%
9
Nature Genetics
240 papers in training set
Top 4%
2.0%
10
Cancers
200 papers in training set
Top 2%
2.0%
11
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.3%
1.8%
12
Theranostics
33 papers in training set
Top 0.5%
1.8%
13
Journal of Hematology & Oncology
10 papers in training set
Top 0.1%
1.7%
14
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.1%
1.7%
15
eLife
5422 papers in training set
Top 44%
1.6%
16
Cancer Discovery
61 papers in training set
Top 1%
1.6%
17
Cancer Letters
32 papers in training set
Top 0.3%
1.4%
18
Clinical Cancer Research
58 papers in training set
Top 1%
1.4%
19
Cell Genomics
162 papers in training set
Top 5%
1.2%
20
Genome Medicine
154 papers in training set
Top 7%
0.9%
21
Cell Reports Medicine
140 papers in training set
Top 7%
0.8%
22
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 1.0%
0.8%
23
Communications Biology
886 papers in training set
Top 22%
0.8%
24
Acta Neuropathologica Communications
81 papers in training set
Top 1%
0.7%
25
Oncogene
76 papers in training set
Top 2%
0.7%
26
Frontiers in Oncology
95 papers in training set
Top 4%
0.7%
27
European Journal of Cancer
10 papers in training set
Top 0.6%
0.7%
28
Annals of Oncology
13 papers in training set
Top 1%
0.7%
29
OncoImmunology
22 papers in training set
Top 0.4%
0.7%
30
eBioMedicine
130 papers in training set
Top 6%
0.6%